Movatterモバイル変換


[0]ホーム

URL:


US20060116510A1 - Isoflavone concentrates, as well as methods for their production - Google Patents

Isoflavone concentrates, as well as methods for their production
Download PDF

Info

Publication number
US20060116510A1
US20060116510A1US11/329,173US32917306AUS2006116510A1US 20060116510 A1US20060116510 A1US 20060116510A1US 32917306 AUS32917306 AUS 32917306AUS 2006116510 A1US2006116510 A1US 2006116510A1
Authority
US
United States
Prior art keywords
concentrate
approximately
weight
isoflavone
polysorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/329,173
Inventor
Dariush Behnam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aquanova AG
Original Assignee
Aquanova AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aquanova AGfiledCriticalAquanova AG
Priority to US11/329,173priorityCriticalpatent/US20060116510A1/en
Publication of US20060116510A1publicationCriticalpatent/US20060116510A1/en
Assigned to AQUANOVA AGreassignmentAQUANOVA AGCHANGE OF NAME (SEE DOCUMENT FOR DETAILS).Assignors: AQUANOVA GERMAN SOLUBILISATE TECHNOLOGIES (AGT) GMBH
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Definitions

Landscapes

Abstract

Isoflavone concentrates are described, which contain at least about ten to about twenty weight parts of polysorbate to one weight part of isoflavone containing a genistein, and/or daidcein, and/or glycitein. Further, a method for the production of an isoflavone concentrate is described.

Description

Claims (12)

1-16. (canceled)
17. An isoflavonoid concentrate containing a polysorbate and a mixture comprising genistein, daidzen, glyceiten, and their glycosides.
18. The isoflavonoid concentrate ofclaim 17, wherein said concentrate contains approximately 83.4% by weight of polysorbate 80 and approximately 6.64% by weight of said mixture.
19. The isoflavonoid concentrate ofclaim 17, wherein said concentrate contains approximately 50% by weight of polysorbate 80, approximately 40% by weight of water and approximately 4% by weight of said mixture.
20. The isoflavonoid concentrate ofclaim 17, wherein said concentrate contains approximately 60% by weight of polysorbate 80, approximately 23% by weight of water, approximately 7% by weight of triglyceride containing plant oil, and approximately 4% by weight of said mixture.
21. The isoflavonoid concentrate ofclaim 17, wherein said polysorbate is polysorbate 80.
22. A finished drink comprising approximately 15% by weight or 25% by weight of the concentrate ofclaim 17.
23. A finished drink comprising approximately 15% by weight or 25% by weight of the concentrate ofclaim 18.
24. A finished drink comprising approximately 15% by weight or 25% by weight of the concentrate ofclaim 19.
25. A finished drink comprising approximately 15% by weight or 25% by weight of the concentrate ofclaim 20.
26. A finished drink comprising approximately 15% by weight or 25% by weight of the concentrate ofclaim 21.
27. Use of the isoflavonoid concentrate ofclaim 17 in cosmetics, nutritional supplements, or body care products.
US11/329,1732002-06-292006-01-11Isoflavone concentrates, as well as methods for their productionAbandonedUS20060116510A1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US11/329,173US20060116510A1 (en)2002-06-292006-01-11Isoflavone concentrates, as well as methods for their production

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
PCT/EP2002/007194WO2004002469A1 (en)2002-06-292002-06-29Isoflavone concentrate and method for production thereof
US10/450,539US7208594B2 (en)2002-06-292002-06-29Isoflavone concentrates as well as methods for their production
US11/329,173US20060116510A1 (en)2002-06-292006-01-11Isoflavone concentrates, as well as methods for their production

Related Parent Applications (3)

Application NumberTitlePriority DateFiling Date
US10/469,541DivisionUS7155097B2 (en)2001-03-092002-03-09Fabrication of microstructured fibres
US10/450,539DivisionUS7208594B2 (en)2002-06-292002-06-29Isoflavone concentrates as well as methods for their production
PCT/EP2002/007194DivisionWO2004002469A1 (en)2002-06-292002-06-29Isoflavone concentrate and method for production thereof

Publications (1)

Publication NumberPublication Date
US20060116510A1true US20060116510A1 (en)2006-06-01

Family

ID=29797108

Family Applications (2)

Application NumberTitlePriority DateFiling Date
US10/450,539Expired - Fee RelatedUS7208594B2 (en)2002-06-292002-06-29Isoflavone concentrates as well as methods for their production
US11/329,173AbandonedUS20060116510A1 (en)2002-06-292006-01-11Isoflavone concentrates, as well as methods for their production

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
US10/450,539Expired - Fee RelatedUS7208594B2 (en)2002-06-292002-06-29Isoflavone concentrates as well as methods for their production

Country Status (12)

CountryLink
US (2)US7208594B2 (en)
EP (1)EP1450786B1 (en)
JP (1)JP2005531616A (en)
AT (1)ATE312605T1 (en)
AU (1)AU2002328824A1 (en)
CA (1)CA2448513A1 (en)
DE (1)DE50205310D1 (en)
DK (1)DK1450786T3 (en)
ES (1)ES2254725T3 (en)
IL (2)IL158569A0 (en)
MX (1)MXPA04002145A (en)
WO (1)WO2004002469A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US8551530B2 (en)2010-11-152013-10-08Humanetics CorporationNanoparticle isoflavone compositions and methods of making and using the same
US9084726B2 (en)2013-11-262015-07-21Humanetics CorporationSuspension compositions of physiologically active phenolic compounds and methods of making and using the same

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JP2005320281A (en)*2004-05-102005-11-17Shiratori Pharmaceutical Co LtdPromotor of insulin secretion and food and drink
EP1904042A2 (en)*2005-07-082008-04-02Aquanova AgSolubilsation products of an active ingredient extract
WO2007070523A2 (en)*2005-12-132007-06-21The Procter & Gamble CompanyPersonal care compositions comprising ppar. gamma. antagonists
EP2129373B1 (en)*2007-04-022013-05-22DSM IP Assets B.V.Use of genistein for treating dry eye syndrome
US8637569B2 (en)2009-10-222014-01-28Api Genesis, LlcMethods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
CA3023725C (en)2009-10-222021-09-14Vizuri Health Sciences LlcMethods of producing hydrated flavonoids and use thereof in the preparation of topical compositions

Citations (55)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4172128A (en)*1975-03-261979-10-23Erhard ThieleProcess of degrading and regenerating bone and tooth material and products
US4563350A (en)*1984-10-241986-01-07Collagen CorporationInductive collagen based bone repair preparations
US5563046A (en)*1993-08-021996-10-08Celtrix Pharmaceuticals, Inc.Fusion polypeptides and proteins
US5608035A (en)*1994-02-021997-03-04Affymax Technologies N.V.Peptides and compounds that bind to the IL-1 receptor
US5635597A (en)*1994-05-271997-06-03Affymax Technologies, N.V.Peptides that bind IL-2 receptors
US5643873A (en)*1992-05-061997-07-01Affymax Technologies N.V.Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en)*1992-05-061997-07-15Affymax Technologies N.V.Peptides and compounds that bind to ELAM-1
US5654276A (en)*1995-06-071997-08-05Affymax Technologies N.V.Peptides and compounds that bind to the IL-5 receptor
US5668110A (en)*1995-06-071997-09-16Affymax Technologies N.V.Peptides and compounds that bind to the IL-5 receptor
US5674977A (en)*1993-02-051997-10-07The Ontario Cancer InstituteBranched synthetic peptide conjugate
US5679673A (en)*1992-09-241997-10-21The United States Of America, Represented By The Department Of Health And Human ServicesAralkyl bridged diazabicycloalkane derivatives for CNS disorders
US5679637A (en)*1989-04-271997-10-21The Salk Institute For Biological StudiesFibroblast growth factor conjugates
US5684136A (en)*1992-05-181997-11-04Genentech, Inc.Chimeric hepatocyte growth factor (HGF) ligand variants
US5728802A (en)*1992-05-061998-03-17Affymax Technologies N.V.Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5759515A (en)*1989-08-091998-06-02Rhomed IncorporatedPolyvalent peptide pharmaceutical applications
US5770704A (en)*1992-05-181998-06-23Genentech, Inc.Receptor activation with inactive hepatocyte growth factor ligands
US5773569A (en)*1993-11-191998-06-30Affymax Technologies N.V.Compounds and peptides that bind to the erythropoietin receptor
US5786331A (en)*1994-02-021998-07-28Affymax Technologies N.V.Peptides and compounds that bind to the IL-1 receptor
US5789182A (en)*1990-12-201998-08-04The Children's Medical Center CorporationSystem for assaying binding to a heparin-binding growth factor receptor
US5824702A (en)*1996-06-071998-10-20Mount Sinai School Of Medicine Of The City University Of New YorkGenistein as a preventive against ultraviolet induced skin photodamage and cancer
US5830851A (en)*1993-11-191998-11-03Affymax Technologies N.V.Methods of administering peptides that bind to the erythropoietin receptor
US5861476A (en)*1994-02-021999-01-19Affymax Technologies N.V.Peptides and compounds that bind to the IL-1 receptor
US5866113A (en)*1996-05-311999-02-02Medtronic, Inc.Medical device with biomolecule-coated surface graft matrix
US5869451A (en)*1995-06-071999-02-09Glaxo Group LimitedPeptides and compounds that bind to a receptor
US5880096A (en)*1994-02-021999-03-09Affymax Technologies N.V.Peptides and compounds that bind to the IL-1 receptor
US5902799A (en)*1989-04-231999-05-11The Trustees Of The University Of PennsylvaniaMethods of modulating tissue growth and regeneration
US5932462A (en)*1995-01-101999-08-03Shearwater Polymers, Inc.Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5952474A (en)*1992-08-281999-09-14The Public Health Research Institute Of The City Of New York, Inc.Fusion glycoproteins
US5955588A (en)*1997-12-221999-09-21Innerdyne, Inc.Non-thrombogenic coating composition and methods for using same
US5965532A (en)*1996-06-281999-10-12Trustees Of Tufts CollegeMultivalent compounds for crosslinking receptors and uses thereof
US5989866A (en)*1996-10-161999-11-23Zymogenetics, Inc.FGF homologs
US5994104A (en)*1996-11-081999-11-30Royal Free Hospital School Of MedicineInterleukin-12 fusion protein
US6001364A (en)*1993-05-051999-12-14Gryphon SciencesHetero-polyoxime compounds and their preparation by parallel assembly
US6011002A (en)*1994-04-082000-01-04The United States Of America As Represented By The Department Of Health And Human ServicesCircularly permuted ligands and circularly permuted chimeric molecules
US6030812A (en)*1992-11-242000-02-29G. D. Searle & CompanyFusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors
US6051648A (en)*1995-12-182000-04-18Cohesion Technologies, Inc.Crosslinked polymer compositions and methods for their use
US6096343A (en)*1997-10-272000-08-01Gerhard GergelyInstant calcium/soybean granules, their use and process for their preparation
US6121236A (en)*1998-03-242000-09-19The Children's Medical Center CorporationMultivalent ligands which modulate angiogenesis
US6168784B1 (en)*1997-09-032001-01-02Gryphon SciencesN-terminal modifications of RANTES and methods of use
US6174721B1 (en)*1994-08-052001-01-16Chiron CorporationChimeric proteins
US6174530B1 (en)*1993-05-052001-01-16Gryphon SciencesHomogeneous polyoxime compositions and their preparation by parallel assembly
US6214795B1 (en)*1996-11-122001-04-10Praecis Pharmaceuticals, Inc.Peptide compounds useful for modulating FGF receptor activity
US6251864B1 (en)*1995-06-072001-06-26Glaxo Group LimitedPeptides and compounds that bind to a receptor
US6261565B1 (en)*1996-03-132001-07-17Archer Daniels Midland CompanyMethod of preparing and using isoflavones
US6284503B1 (en)*1993-08-202001-09-04University Of Utah Research FoundationComposition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces
US6294359B1 (en)*1985-09-122001-09-25Scios Inc.Human basic fibroblast growth factor analog
US6300377B1 (en)*2001-02-222001-10-09Raj K. ChopraCoenzyme Q products exhibiting high dissolution qualities
US6323323B1 (en)*1988-01-222001-11-27Zymogenetics, Inc.Ligand-binding, dimerized polypeptide fusions
US6326468B1 (en)*1997-06-132001-12-04Gryphon SciencesSolid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
US6342591B1 (en)*1998-09-222002-01-29Biosurface Engineering Technologies, Inc.Amphipathic coating for modulating cellular adhesion composition and methods
US6350731B1 (en)*1993-10-222002-02-26Trigen LimitedPlatelet-derived growth factor analogues
US6377349B1 (en)*1998-03-302002-04-23Carl Zeiss Jena GmbhArrangement for spectral interferometric optical tomography and surface profile measurement
US6451543B1 (en)*1998-08-312002-09-17Gryphon SciencesLipid matrix-assisted chemical ligation and synthesis of membrane polypeptides
US6495718B1 (en)*1999-05-262002-12-17Nutrinova Nutrition Specialties & Food Ingredients GmbhMethod for suppressing sorbate- and/or sorbic acid-induced discoloration
US20030224996A1 (en)*1988-04-082003-12-04Stryker CorporationOsteogenic devices

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CA2010894A1 (en)*1989-02-281990-08-31Isamu HorikoshiMethod of forming a suspension and composition formed by said method
WO1999038509A1 (en)1998-01-281999-08-05Dusan MiljkovicIsoflavanoid formulations for oral administration
DE10104847B4 (en)2000-06-092006-12-21Aquanova German Solubilisate Technologies (Agt) Gmbh Tocopherol concentrate and process for its preparation
DE10103454A1 (en)*2000-12-292002-08-01Aquanova GetraenketechnologieFlavonoid concentrate useful in foods, body care products and cosmetics comprises a polysorbate and isoflavones and/or quercetin
DE50211435D1 (en)2001-02-112008-02-07Aquanova Ag Process for the preparation of a drug concentrate and drug concentrate

Patent Citations (59)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4172128A (en)*1975-03-261979-10-23Erhard ThieleProcess of degrading and regenerating bone and tooth material and products
US4563350A (en)*1984-10-241986-01-07Collagen CorporationInductive collagen based bone repair preparations
US6294359B1 (en)*1985-09-122001-09-25Scios Inc.Human basic fibroblast growth factor analog
US6323323B1 (en)*1988-01-222001-11-27Zymogenetics, Inc.Ligand-binding, dimerized polypeptide fusions
US20030224996A1 (en)*1988-04-082003-12-04Stryker CorporationOsteogenic devices
US5902799A (en)*1989-04-231999-05-11The Trustees Of The University Of PennsylvaniaMethods of modulating tissue growth and regeneration
US5679637A (en)*1989-04-271997-10-21The Salk Institute For Biological StudiesFibroblast growth factor conjugates
US5759515A (en)*1989-08-091998-06-02Rhomed IncorporatedPolyvalent peptide pharmaceutical applications
US5789182A (en)*1990-12-201998-08-04The Children's Medical Center CorporationSystem for assaying binding to a heparin-binding growth factor receptor
US5786322A (en)*1992-05-061998-07-28Affymax Technologies N.V.Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1
US5648458A (en)*1992-05-061997-07-15Affymax Technologies N.V.Peptides and compounds that bind to ELAM-1
US5728802A (en)*1992-05-061998-03-17Affymax Technologies N.V.Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en)*1992-05-061997-07-01Affymax Technologies N.V.Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5770704A (en)*1992-05-181998-06-23Genentech, Inc.Receptor activation with inactive hepatocyte growth factor ligands
US5684136A (en)*1992-05-181997-11-04Genentech, Inc.Chimeric hepatocyte growth factor (HGF) ligand variants
US5952474A (en)*1992-08-281999-09-14The Public Health Research Institute Of The City Of New York, Inc.Fusion glycoproteins
US5679673A (en)*1992-09-241997-10-21The United States Of America, Represented By The Department Of Health And Human ServicesAralkyl bridged diazabicycloalkane derivatives for CNS disorders
US6030812A (en)*1992-11-242000-02-29G. D. Searle & CompanyFusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors
US5674977A (en)*1993-02-051997-10-07The Ontario Cancer InstituteBranched synthetic peptide conjugate
US6001364A (en)*1993-05-051999-12-14Gryphon SciencesHetero-polyoxime compounds and their preparation by parallel assembly
US6217873B1 (en)*1993-05-052001-04-17Gryphon SciencesPolyoxime compounds and their preparation
US6174530B1 (en)*1993-05-052001-01-16Gryphon SciencesHomogeneous polyoxime compositions and their preparation by parallel assembly
US5563046A (en)*1993-08-021996-10-08Celtrix Pharmaceuticals, Inc.Fusion polypeptides and proteins
US6284503B1 (en)*1993-08-202001-09-04University Of Utah Research FoundationComposition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces
US6350731B1 (en)*1993-10-222002-02-26Trigen LimitedPlatelet-derived growth factor analogues
US5773569A (en)*1993-11-191998-06-30Affymax Technologies N.V.Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en)*1993-11-191998-11-03Affymax Technologies N.V.Methods of administering peptides that bind to the erythropoietin receptor
US5880096A (en)*1994-02-021999-03-09Affymax Technologies N.V.Peptides and compounds that bind to the IL-1 receptor
US5786331A (en)*1994-02-021998-07-28Affymax Technologies N.V.Peptides and compounds that bind to the IL-1 receptor
US5608035A (en)*1994-02-021997-03-04Affymax Technologies N.V.Peptides and compounds that bind to the IL-1 receptor
US5861476A (en)*1994-02-021999-01-19Affymax Technologies N.V.Peptides and compounds that bind to the IL-1 receptor
US5767234A (en)*1994-02-021998-06-16Affymax Technologies, N.V.Peptides and compounds that bind to the IL-1 receptor
US6011002A (en)*1994-04-082000-01-04The United States Of America As Represented By The Department Of Health And Human ServicesCircularly permuted ligands and circularly permuted chimeric molecules
US5635597A (en)*1994-05-271997-06-03Affymax Technologies, N.V.Peptides that bind IL-2 receptors
US6174721B1 (en)*1994-08-052001-01-16Chiron CorporationChimeric proteins
US5932462A (en)*1995-01-101999-08-03Shearwater Polymers, Inc.Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5668110A (en)*1995-06-071997-09-16Affymax Technologies N.V.Peptides and compounds that bind to the IL-5 receptor
US6251864B1 (en)*1995-06-072001-06-26Glaxo Group LimitedPeptides and compounds that bind to a receptor
US5869451A (en)*1995-06-071999-02-09Glaxo Group LimitedPeptides and compounds that bind to a receptor
US5654276A (en)*1995-06-071997-08-05Affymax Technologies N.V.Peptides and compounds that bind to the IL-5 receptor
US6051648A (en)*1995-12-182000-04-18Cohesion Technologies, Inc.Crosslinked polymer compositions and methods for their use
US6261565B1 (en)*1996-03-132001-07-17Archer Daniels Midland CompanyMethod of preparing and using isoflavones
US5866113A (en)*1996-05-311999-02-02Medtronic, Inc.Medical device with biomolecule-coated surface graft matrix
US5824702A (en)*1996-06-071998-10-20Mount Sinai School Of Medicine Of The City University Of New YorkGenistein as a preventive against ultraviolet induced skin photodamage and cancer
US5965532A (en)*1996-06-281999-10-12Trustees Of Tufts CollegeMultivalent compounds for crosslinking receptors and uses thereof
US5989866A (en)*1996-10-161999-11-23Zymogenetics, Inc.FGF homologs
US5994104A (en)*1996-11-081999-11-30Royal Free Hospital School Of MedicineInterleukin-12 fusion protein
US6214795B1 (en)*1996-11-122001-04-10Praecis Pharmaceuticals, Inc.Peptide compounds useful for modulating FGF receptor activity
US6326468B1 (en)*1997-06-132001-12-04Gryphon SciencesSolid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
US6168784B1 (en)*1997-09-032001-01-02Gryphon SciencesN-terminal modifications of RANTES and methods of use
US6096343A (en)*1997-10-272000-08-01Gerhard GergelyInstant calcium/soybean granules, their use and process for their preparation
US5955588A (en)*1997-12-221999-09-21Innerdyne, Inc.Non-thrombogenic coating composition and methods for using same
US6235716B1 (en)*1998-03-242001-05-22Children's Medical Center CorporationMultivalent ligands which modulate angiogenesis
US6121236A (en)*1998-03-242000-09-19The Children's Medical Center CorporationMultivalent ligands which modulate angiogenesis
US6377349B1 (en)*1998-03-302002-04-23Carl Zeiss Jena GmbhArrangement for spectral interferometric optical tomography and surface profile measurement
US6451543B1 (en)*1998-08-312002-09-17Gryphon SciencesLipid matrix-assisted chemical ligation and synthesis of membrane polypeptides
US6342591B1 (en)*1998-09-222002-01-29Biosurface Engineering Technologies, Inc.Amphipathic coating for modulating cellular adhesion composition and methods
US6495718B1 (en)*1999-05-262002-12-17Nutrinova Nutrition Specialties & Food Ingredients GmbhMethod for suppressing sorbate- and/or sorbic acid-induced discoloration
US6300377B1 (en)*2001-02-222001-10-09Raj K. ChopraCoenzyme Q products exhibiting high dissolution qualities

Cited By (12)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US8551530B2 (en)2010-11-152013-10-08Humanetics CorporationNanoparticle isoflavone compositions and methods of making and using the same
US8900635B2 (en)2010-11-152014-12-02Humanetics CorporationNanoparticle isoflavone compositions and methods of making and using the same
US9308167B2 (en)2010-11-152016-04-12Humanetics CorporationNanoparticle isoflavone compositions and methods of making and using the same
US9636322B2 (en)2010-11-152017-05-02Humanetics CorporationNanoparticle isoflavone compositions and methods of making and using the same
US9724325B2 (en)2010-11-152017-08-08Humanetics CorporationNanoparticle isoflavone compositions and methods of making and using the same
US10039739B2 (en)2010-11-152018-08-07Humanetics CorporationNanoparticle isoflavone compositions and methods of making and using the same
US10729674B2 (en)2010-11-152020-08-04Humanetics CorporationNanoparticle isoflavone compositions and methods of making and using the same
US9084726B2 (en)2013-11-262015-07-21Humanetics CorporationSuspension compositions of physiologically active phenolic compounds and methods of making and using the same
US9387171B2 (en)2013-11-262016-07-12Humanetics CorporationSuspension compositions of physiologically active phenolic compounds and methods of making and using the same
US9782384B2 (en)2013-11-262017-10-10Humanetics CorporationSuspension compositions of physiologically active phenolic compounds and methods of making and using the same
US9937148B2 (en)2013-11-262018-04-10Humanetics CorporationSuspension compositions of physiologically active phenolic compounds and methods of making and using the same
US10314812B2 (en)2013-11-262019-06-11Humanetics CorporationSuspension compositions of physiologically active phenolic compounds and methods of making and using the same

Also Published As

Publication numberPublication date
AU2002328824A1 (en)2004-01-19
DE50205310D1 (en)2006-01-19
ATE312605T1 (en)2005-12-15
ES2254725T3 (en)2006-06-16
CA2448513A1 (en)2003-12-29
JP2005531616A (en)2005-10-20
WO2004002469A1 (en)2004-01-08
HK1071512A1 (en)2005-07-22
US20040220116A1 (en)2004-11-04
MXPA04002145A (en)2005-03-07
IL158569A (en)2008-12-29
DK1450786T3 (en)2006-04-18
IL158569A0 (en)2004-05-12
US7208594B2 (en)2007-04-24
EP1450786B1 (en)2005-12-14
EP1450786A1 (en)2004-09-01

Similar Documents

PublicationPublication DateTitle
US20060116510A1 (en)Isoflavone concentrates, as well as methods for their production
CN105228470B (en)Vitamin E soluble derivative preparation and composition comprising it
Stanisavljević et al.Antioxidant and antiproliferative activity of chokeberry juice phenolics during in vitro simulated digestion in the presence of food matrix
YangBrazil nuts and associated health benefits: A review
Fraga et al.Basic biochemical mechanisms behind the health benefits of polyphenols
O'Keefe et al.Soybean nutrition
Tew et al.A diet high in wheat fiber decreases the bioavailability of soybean isoflavones in a single meal fed to women
JP4668553B2 (en) Epigallocatechin dimer and trimer having lipase inhibitory activity and / or antioxidant activity
EP0914111A2 (en)Method for the prevention and treatment of cachexia and anorexia
CN104427887A (en)Nutritional compositions including rrr -alpha tocopherol and polyunsaturated fatty acids
Pejčić et al.The polyphenols as potential agents in prevention and therapy of prostate diseases
Kaharso et al.Quality improvement of soymilk as influenced by anaerobic grinding method and calcium addition
US6251420B1 (en)Isoflavanoid formulations for oral administration
JP2005525335A (en) N-acyl-phosphatidyl-ethanolamines and / or mixtures of N-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
Sanz et al.Release, partitioning and stability of isoflavones from enriched custards during mouth, stomach and intestine in vitro simulations
CN105072925A (en)A composition for enhancing newborn infant cognitive, brain and/or cns development and method of using same
US5932221A (en)Genistin-enriched fraction from soy meal
JP2003153650A (en)Edible oil and fat, and food product using the same
WO2005115472A2 (en)Compositions comprising gamma-linolenic acid and iodine for improving breast health in women
HK1071512B (en)Isoflavone concentrate and method for production thereof
Antoine et al.Impact of pulses, starches and meat on vitamin D and K postprandial responses in mice
Wijayanti et al.Administration of Mung Bean Extract (Phaseolus radiatus) in Increasing Hb and Ferritin Level and Decreasing Malondyaldehide (MDA) Level in Anaemic Rats.
MX2008001791A (en)Food product and fortification system therefor.
JPH119221A (en)Antiosteoporotic composition
WO2001087315A1 (en)Treatment or prevention of metabolic bone disorder

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:AQUANOVA AG, GERMANY

Free format text:CHANGE OF NAME;ASSIGNOR:AQUANOVA GERMAN SOLUBILISATE TECHNOLOGIES (AGT) GMBH;REEL/FRAME:019353/0674

Effective date:20061026

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION


[8]ページ先頭

©2009-2025 Movatter.jp